<DOC>
	<DOCNO>NCT01209286</DOCNO>
	<brief_summary>The purpose study determine whether bispecific T-cell engager blinatumomab effective , safe tolerable treatment patient relapsed/refractory B-precursor ALL .</brief_summary>
	<brief_title>Study BiTE® Blinatumomab ( MT103 ) Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>Relapsed/refractory B-precursor ALL adult patient aggressive malignant disease dismal prognosis unmet medical need . Additional therapeutic approach urgently need . Blinatumomab bispecific single-chain antibody construct design link B cell T cell result T cell activation cytotoxic T cell response CD19 express cell . The purpose study investigate efficacy , safety tolerability different dos bispecific T-cell engager blinatumomab adult patient relapsed/refractory B-precursor ALL . Patrticipants receive five 4-week cycle intravenous blinatumomab treatment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Patients Bprecursor ALL relapse least induction consolidation refractory disease More 5 % blast bone marrow Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Life expectancy ≥ 12 week History presence clinically relevant central nervous system ( CNS ) pathology Infiltration cerebrospinal fluid ( CSF ) ALL Autologous/allogeneic hematopoietic stem cell transplantation ( HSCT ) within six weeks/three month prior start blinatumomab treatment Active GraftversusHost Disease ( GvHD ) Patients Philadelphia chromosome ( Ph ) + ALL eligible treatment dasatinib imatinib Cancer chemotherapy within two week prior start blinatumomab treatment Immunotherapy ( e.g . rituximab ) within four week prior start blinatumomab treatment Infection human immunodeficiency virus ( HIV ) hepatitis B ( HBsAg positive ) hepatitis C virus ( antiHCV positive ) Pregnant nursing woman Previous treatment blinatumomab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Blinatumomab</keyword>
	<keyword>B-ALL</keyword>
	<keyword>adult ALL</keyword>
	<keyword>relapse ALL</keyword>
	<keyword>refractory ALL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Lymphatic disease</keyword>
	<keyword>Lymphoproliferative disorder</keyword>
	<keyword>bispecific antibody</keyword>
	<keyword>anti-CD19</keyword>
	<keyword>Immunotherapeutic treatment</keyword>
</DOC>